Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10928-009-9138-4PMID 19941044
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.

  2008influential reference
• Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype

  2007cited by this paper
• Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

  2006influential reference
• Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

  2006cited by this paper
• A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

  2006cited by this paper
• Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic‐Pharmacodynamic Modeling Approach

  2006cited by this paper
• Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

  2006cited by this paper
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005influential reference
• A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

  2005cited by this paper
• Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

  2005cited by this paper
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

  2005cited by this paper
• Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

  2005cited by this paper
• VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

  2005cited by this paper
• Functional Characterization of Novel Allelic Variants of CYP2C9 Recently Discovered in Southeast Asians

  2005cited by this paper
• Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

  2004cited by this paper
• Novel CYP2C9 genetic variants in asian subjects and their influence on maintenance warfarin dose

  2004influential reference
• Identification of the gene for vitamin K epoxide reductase

  2004cited by this paper
• Bayesian Analysis of Population PK/PD Models: General Concepts and Software

  2002cited by this paper
• Changes in plasma protein binding have little clinical relevance

  2002cited by this paper
• Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin.

  2001cited by this paper
• Cytochrome P450 polymorphisms are associated with reduced warfarin dose.

  2000cited by this paper
• Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0

  1999cited by this paper
• Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

  1998cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic‐pharmacodynamic model

  1994cited by this paper
• Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults

  1993cited by this paper
• Vitamin K metabolism and vitamin K1 status in human liver samples: a search for inter‐individual differences in warfarin sensitivity

  1993influential reference
• Reversible metabolism of vitamin K-vitamin K epoxide: Modeling considerations and limitations

  1992influential reference
• Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase.

  1990cited by this paper
• Effect of warfarin on plasma and liver vitamin K levels and vitamin K epoxide reductase activity in relation to plasma clotting factor levels in rats.

  1990influential reference
• Clinical Pharmacokinetics and Pharmacodynamics of Warfarin

  1986cited by this paper
• Goodman and Gilman's the Pharmacological Basis of Therapeutics

  1986cited by this paper
• Cyclic interconversion of vitamin K1 and vitamin K1 2,3-epoxide in man.

  1983cited by this paper
• Dosage and control of oral anticoagulants: an international collaborative survey

  1982cited by this paper
• Vitamin K1, vitamin K1 epoxide and warfarin interrelationships in the dog.

  1981cited by this paper
• Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.

  1974cited by this paper
• The Pharmacological Basis of Therapeutics

  1941cited by this paper

• High occurrence of antiphospholipid antibody-associated thromboembolism in systemic lupus erythematosus with significant pulmonary hypertension: A monocentric retrospective study in southern taiwan.

  2025cites this paper
• Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle–Income Country Setting

  2024cites this paper
• Warfarin-A natural anticoagulant: A review of research trends for precision medication.

  2024cites this paper
• Development and validation wise assessment of genotype guided warfarin dosing algorithm in Indian population

  2023cites this paper
• Is TXA beneficial in open spine surgery? And its effects vary by dosage, age, sites, and locations: A meta-analysis of randomized controlled trials.

  2022cites this paper
• Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry

  2020cites this paper
• SAMe-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation.

  2019cites this paper
• Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study

  2018cites this paper
• Application of pharmacometric methods to understand warfarin dose response

  2018influential citation
• CHAPTER 2 . 5 Pharmacogenomics research and practice : Snapshots from Malaysia

  2018cites this paper
• The Clinical Pharmacokinetics and Pharmacodynamics of Warfarin When Combined with Compound Danshen: A Case Study for Combined Treatment of Coronary Heart Diseases with Atrial Fibrillation

  2017influential citation
• Aging, Genetic Variations, and Ethnopharmacology

  2017cites this paper
• Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement

  2017cites this paper
• Theory‐based pharmacokinetics and pharmacodynamics of S‐ and R‐warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients

  2017cites this paper
• A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins

  2017cites this paper
• Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice

  2017cites this paper
• Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.

  2016cites this paper
• Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians

  2016cites this paper
• Genetic Polymorphisms of VKORC1 in Han Population of Yunnan China*

  2015cites this paper
• Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?

  2015cites this paper
• Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial

  2014cites this paper
• single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

  2013cites this paper
• Modeling and Simulation as a Tool to Bridge Efficacy and Safety Data in Special Populations

  2013cites this paper
• Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors

  2013cites this paper
• Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.

  2013cites this paper
• Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

  2013cites this paper
• Allele and Genotype frequencies of VKORC1 -1639G>A polymorphism in three different ethnic groups in Malaysia

  2012cites this paper
• Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

  2012cites this paper
• Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients

  2012cites this paper
• Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population.

  2012cites this paper
• Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

  2011cites this paper
• Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations

  2011cites this paper
• A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan

  2011cites this paper
• Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation

  2011cites this paper
• Regions of homozygosity in three Southeast Asian populations

  2011cites this paper
• The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement

  2011cites this paper
• The Creating an Optimal Warfarin Nomogram (CROWN) Study

  2011cites this paper
• Optimization of warfarin dose by population-specific pharmacogenomic algorithm

  2011cites this paper
• Clinical Pharmacology: Advances and Applications Dovepress Single-and Multiple-dose Pharmacokinetics, Pharmacodynamics, and Safety of Apixaban in Healthy Chinese Subjects

  year unknowncites this paper